Heparan sulfate mediates neuroprotection from degeneration in experimental glutaric aciduria

Michelle C. Naylor, Mesfin Negia, Meredith Noetzel, Terence Burns, Zach L. Demorest, Walter C. Low

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Glutaric aciduria type 1 (GA1) is a childhood metabolic disorder associated with crises that lead to striatal necrosis. Although the disorder can be controlled with diet, there is no current treatment to ameliorate the neurodegeneration following a metabolic crisis. We hypothesized that heparan sulfate (HS) administration would stimulate neural stem cell proliferation by dimerizing with FGF-2 and binding to the FGF-2 receptor on neural stem cells, thus enhancing the number of newly generated neurons to repair damage following a metabolic crisis. In addition, FGF-2 is known to exert neuroprotective effects independent of neurogenesis, so HS may also have neuroprotective activities. To test these hypotheses, ibotenic acid was injected into the striatum of adult mice, mimicking the metabolic crisis and damage caused by glutaric aciduria. Daily doses of HS and bromodeoxyuridine (BrdU) or BrdU alone were administered starting 1 day after the ibotenic acid lesion. BrdU was used to label dividing cells. Fluorescent immunohistochemistry was used to quantify the lesion size and evaluate the phenotype of BrdU-positive cells. Intrastriatal administration of ibotenic acid resulted in a substantial striatal lesion that occupied 18.5% of the ipsilateral brain hemisphere. In contrast, animals treated with HS exhibited a lesion volume representing <1% of the ipsilateral brain hemisphere (ANOVA; p < 0.0001). Increased neurogenesis, however, was not observed in this group. These results suggest that HS administration 2 days after a "metabolic crisis" can ameliorate brain injury in an animal model of GA1. The neuroprotective mechanisms of HS, however, remain to be elucidated but may exert their actions indirectly through binding with FGF-2.

Original languageEnglish (US)
Pages (from-to)187-195
Number of pages9
JournalCell Transplantation
Volume16
Issue number3
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Heparitin Sulfate
Fibroblast Growth Factor 2
Ibotenic Acid
Bromodeoxyuridine
Corpus Striatum
Brain
Neural Stem Cells
Neurogenesis
Stem cells
Acids
Animals
Fibroblast Growth Factor Receptors
Cell proliferation
Neuroprotective Agents
Nutrition
Analysis of variance (ANOVA)
Brain Injuries
Neurons
Neuroprotection
Sulfates

Keywords

  • Bromodeoxyuridine
  • FGF2
  • Glutaric aciduria
  • Heparan sulfate
  • Striatal necrosis

ASJC Scopus subject areas

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Cite this

Heparan sulfate mediates neuroprotection from degeneration in experimental glutaric aciduria. / Naylor, Michelle C.; Negia, Mesfin; Noetzel, Meredith; Burns, Terence; Demorest, Zach L.; Low, Walter C.

In: Cell Transplantation, Vol. 16, No. 3, 01.01.2007, p. 187-195.

Research output: Contribution to journalArticle

Naylor, Michelle C. ; Negia, Mesfin ; Noetzel, Meredith ; Burns, Terence ; Demorest, Zach L. ; Low, Walter C. / Heparan sulfate mediates neuroprotection from degeneration in experimental glutaric aciduria. In: Cell Transplantation. 2007 ; Vol. 16, No. 3. pp. 187-195.
@article{69716369c2274501bb67101957c00b97,
title = "Heparan sulfate mediates neuroprotection from degeneration in experimental glutaric aciduria",
abstract = "Glutaric aciduria type 1 (GA1) is a childhood metabolic disorder associated with crises that lead to striatal necrosis. Although the disorder can be controlled with diet, there is no current treatment to ameliorate the neurodegeneration following a metabolic crisis. We hypothesized that heparan sulfate (HS) administration would stimulate neural stem cell proliferation by dimerizing with FGF-2 and binding to the FGF-2 receptor on neural stem cells, thus enhancing the number of newly generated neurons to repair damage following a metabolic crisis. In addition, FGF-2 is known to exert neuroprotective effects independent of neurogenesis, so HS may also have neuroprotective activities. To test these hypotheses, ibotenic acid was injected into the striatum of adult mice, mimicking the metabolic crisis and damage caused by glutaric aciduria. Daily doses of HS and bromodeoxyuridine (BrdU) or BrdU alone were administered starting 1 day after the ibotenic acid lesion. BrdU was used to label dividing cells. Fluorescent immunohistochemistry was used to quantify the lesion size and evaluate the phenotype of BrdU-positive cells. Intrastriatal administration of ibotenic acid resulted in a substantial striatal lesion that occupied 18.5{\%} of the ipsilateral brain hemisphere. In contrast, animals treated with HS exhibited a lesion volume representing <1{\%} of the ipsilateral brain hemisphere (ANOVA; p < 0.0001). Increased neurogenesis, however, was not observed in this group. These results suggest that HS administration 2 days after a {"}metabolic crisis{"} can ameliorate brain injury in an animal model of GA1. The neuroprotective mechanisms of HS, however, remain to be elucidated but may exert their actions indirectly through binding with FGF-2.",
keywords = "Bromodeoxyuridine, FGF2, Glutaric aciduria, Heparan sulfate, Striatal necrosis",
author = "Naylor, {Michelle C.} and Mesfin Negia and Meredith Noetzel and Terence Burns and Demorest, {Zach L.} and Low, {Walter C.}",
year = "2007",
month = "1",
day = "1",
doi = "10.3727/000000007783464786",
language = "English (US)",
volume = "16",
pages = "187--195",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "3",

}

TY - JOUR

T1 - Heparan sulfate mediates neuroprotection from degeneration in experimental glutaric aciduria

AU - Naylor, Michelle C.

AU - Negia, Mesfin

AU - Noetzel, Meredith

AU - Burns, Terence

AU - Demorest, Zach L.

AU - Low, Walter C.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Glutaric aciduria type 1 (GA1) is a childhood metabolic disorder associated with crises that lead to striatal necrosis. Although the disorder can be controlled with diet, there is no current treatment to ameliorate the neurodegeneration following a metabolic crisis. We hypothesized that heparan sulfate (HS) administration would stimulate neural stem cell proliferation by dimerizing with FGF-2 and binding to the FGF-2 receptor on neural stem cells, thus enhancing the number of newly generated neurons to repair damage following a metabolic crisis. In addition, FGF-2 is known to exert neuroprotective effects independent of neurogenesis, so HS may also have neuroprotective activities. To test these hypotheses, ibotenic acid was injected into the striatum of adult mice, mimicking the metabolic crisis and damage caused by glutaric aciduria. Daily doses of HS and bromodeoxyuridine (BrdU) or BrdU alone were administered starting 1 day after the ibotenic acid lesion. BrdU was used to label dividing cells. Fluorescent immunohistochemistry was used to quantify the lesion size and evaluate the phenotype of BrdU-positive cells. Intrastriatal administration of ibotenic acid resulted in a substantial striatal lesion that occupied 18.5% of the ipsilateral brain hemisphere. In contrast, animals treated with HS exhibited a lesion volume representing <1% of the ipsilateral brain hemisphere (ANOVA; p < 0.0001). Increased neurogenesis, however, was not observed in this group. These results suggest that HS administration 2 days after a "metabolic crisis" can ameliorate brain injury in an animal model of GA1. The neuroprotective mechanisms of HS, however, remain to be elucidated but may exert their actions indirectly through binding with FGF-2.

AB - Glutaric aciduria type 1 (GA1) is a childhood metabolic disorder associated with crises that lead to striatal necrosis. Although the disorder can be controlled with diet, there is no current treatment to ameliorate the neurodegeneration following a metabolic crisis. We hypothesized that heparan sulfate (HS) administration would stimulate neural stem cell proliferation by dimerizing with FGF-2 and binding to the FGF-2 receptor on neural stem cells, thus enhancing the number of newly generated neurons to repair damage following a metabolic crisis. In addition, FGF-2 is known to exert neuroprotective effects independent of neurogenesis, so HS may also have neuroprotective activities. To test these hypotheses, ibotenic acid was injected into the striatum of adult mice, mimicking the metabolic crisis and damage caused by glutaric aciduria. Daily doses of HS and bromodeoxyuridine (BrdU) or BrdU alone were administered starting 1 day after the ibotenic acid lesion. BrdU was used to label dividing cells. Fluorescent immunohistochemistry was used to quantify the lesion size and evaluate the phenotype of BrdU-positive cells. Intrastriatal administration of ibotenic acid resulted in a substantial striatal lesion that occupied 18.5% of the ipsilateral brain hemisphere. In contrast, animals treated with HS exhibited a lesion volume representing <1% of the ipsilateral brain hemisphere (ANOVA; p < 0.0001). Increased neurogenesis, however, was not observed in this group. These results suggest that HS administration 2 days after a "metabolic crisis" can ameliorate brain injury in an animal model of GA1. The neuroprotective mechanisms of HS, however, remain to be elucidated but may exert their actions indirectly through binding with FGF-2.

KW - Bromodeoxyuridine

KW - FGF2

KW - Glutaric aciduria

KW - Heparan sulfate

KW - Striatal necrosis

UR - http://www.scopus.com/inward/record.url?scp=34250667942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250667942&partnerID=8YFLogxK

U2 - 10.3727/000000007783464786

DO - 10.3727/000000007783464786

M3 - Article

C2 - 17503732

AN - SCOPUS:34250667942

VL - 16

SP - 187

EP - 195

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 3

ER -